Archive · 1 Jan 2026
Lilly Leads GLP-1 Weight-Loss Drug Sales in 2025
In 2025, Lilly is doing much better than Novo Nordisk in selling weight-loss and diabetes drugs.
Lilly's stock has gone up by nearly 40%, and it's expected to have sold a lot more of these drugs, about 60% more.
Novo Nordisk, on the other hand, has seen its stock fall by about the same amount.
Their weight-loss drugs grew by 20%, but their total sales only grew by 5%.
An analyst thinks Lilly is a good buy, but Novo Nordisk is just okay to hold.
Lilly's stock is up nearly 40% in 2025.
Lilly's sales of weight-loss and diabetes drugs are expected to grow by 60%.
Novo Nordisk's stock has fallen by roughly 40% in 2025.
Novo Nordisk's weight-loss drug sales are expected to grow by 20%.
Novo Nordisk's total sales are expected to grow by only 5%.
- Who
- Lilly and Novo Nordisk
- What
- Sales performance of weight-loss and diabetes drugs in 2025
- When
- 2025
- Where
- Global market
- Why
- Market demand for weight-loss and diabetes drugs
- Lilly Stock Performance
- Up nearly 40% in 2025
- Lilly Sales Growth
- Expected 60% growth in weight-loss and diabetes drugs
- Novo Nordisk Stock Performance
- Down roughly 40% in 2025
- Novo Nordisk Weight-Loss Drug Growth
- Expected 20% growth
- Novo Nordisk Total Sales Growth
- Expected 5% growth
- Analyst Ratings
- Buy for Lilly, Hold for Novo Nordisk